Work

P-228 Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer: SWOG S2107

Year: 2023

Type: conference-abstract

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2023.04.284

Authors: V. Morris, K. Guthrie, S. Kopetz, R. Breakstone, T. Karasic, Z. Hu, S. Colby, M. Fakih, S. Gholami, P. Gold, E. Chiorean, P. Philip

Institutions: The University of Texas MD Anderson Cancer Center, Fred Hutch Cancer Center, Brown University, University of Pennsylvania, City Of Hope National Medical Center, City of Hope, Northwell Health, Swedish Medical Center, University of Washington, The Barbara Ann Karmanos Cancer Institute

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Korean Foundation for Cancer Research, National Institutes of Health, National Cancer Institute

Awards: G1548551769, G1938688226, NRG Oncology Network Group Operations Center

OpenAlex ID: W4382799172

Cites:

Cited by: 2

Related to: 10